MedTrace Logo

Study of Acamprosate in Driving Under the Influence (DUI) Court Participants

NCT00425711 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2026-04-06

No results posted yet for this study

Summary

Acamprosate will be given to approximately 30 DUI Court participants for 3 months and outcomes will be monitored. The hypothesis is that acamprosate will be safe and well-tolerated and that subjects' craving and other symptoms related to addiction will improve over time.

Conditions

  • Alcohol Dependence

Interventions

DRUG

Acamprosate

Acamprosate 666 mg tid, or 333 tid in renal impairment, for 12 weeks

Sponsors & Collaborators

  • Forest Laboratories

    collaborator INDUSTRY

  • University of Oklahoma

    lead OTHER

Principal Investigators

  • Julia K Warnock, M.D., Ph.D. · University of Oklahoma

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00425711 on ClinicalTrials.gov